Piotr Ozierański

1.4k total citations · 1 hit paper
56 papers, 926 citations indexed

About

Piotr Ozierański is a scholar working on Economics and Econometrics, Pharmacology and General Health Professions. According to data from OpenAlex, Piotr Ozierański has authored 56 papers receiving a total of 926 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Economics and Econometrics, 37 papers in Pharmacology and 23 papers in General Health Professions. Recurrent topics in Piotr Ozierański's work include Pharmaceutical industry and healthcare (37 papers), Pharmaceutical Economics and Policy (36 papers) and Health Systems, Economic Evaluations, Quality of Life (22 papers). Piotr Ozierański is often cited by papers focused on Pharmaceutical industry and healthcare (37 papers), Pharmaceutical Economics and Policy (36 papers) and Health Systems, Economic Evaluations, Quality of Life (22 papers). Piotr Ozierański collaborates with scholars based in United Kingdom, Sweden and Hungary. Piotr Ozierański's co-authors include Shai Mulinari, Martin McKee, Lawrence King, Mary Dixon‐Woods, Graham Martin, Joel T. Minion, Janet Willars, Kathryn Charles, Marcell Csanádi and Jeremy Dawson and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Social Science & Medicine.

In The Last Decade

Piotr Ozierański

54 papers receiving 902 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Culture and behaviour in the English National Health Service: overview of lessons from a large multimethod study

2013 305 citations Mary Dixon‐Woods, Martin McKee et al. profile →

Peers

Piotr Ozierański

GHP

PHARM

HIM

PHEOH

Sandra Feibelmann United States

Racha Fadlallah Lebanon

Stephanie S. Teleki United States

Jill R. Horwitz United States

Cynthia Smith United States

Linda Dynan United States

Jacqueline Cumming New Zealand

David Chinitz Israel

Peter Sivey Australia

Timothy Lake United States

Sandra Feibelmann United States

Piotr Ozierański

199 ×0.5

378 ×1.0

GHP

200 ×0.6

PHARM

98 ×0.7

HIM

160 ×1.4

PHEOH

Citations per year, relative to Piotr Ozierański Piotr Ozierański (= 1×) peers Sandra Feibelmann

Countries citing papers authored by Piotr Ozierański

Since Specialization

Citations

This map shows the geographic impact of Piotr Ozierański's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piotr Ozierański with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piotr Ozierański more than expected).

Fields of papers citing papers by Piotr Ozierański

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piotr Ozierański. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piotr Ozierański. The network helps show where Piotr Ozierański may publish in the future.

Co-authorship network of co-authors of Piotr Ozierański

This figure shows the co-authorship network connecting the top 25 collaborators of Piotr Ozierański. A scholar is included among the top collaborators of Piotr Ozierański based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piotr Ozierański. Piotr Ozierański is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Murayama, Anju, et al.. (2024). Pharmaceutical industry payments to healthcare professional organisations in the United Kingdom: a seven-year cross-sectional analysis of the Disclosure UK database from 2015 to 2021. Journal of the Royal Society of Medicine. 118(1). 16–25. 1 indexed citations

Ozierański, Piotr, et al.. (2023). Professional stakeholders’ expectations for the future of community pharmacy practice in England: a qualitative study. BMJ Open. 13(10). e075069–e075069. 4 indexed citations

Murayama, Anju, Sae Kamamoto, Hiroaki Saito, et al.. (2023). Characteristics and Distribution of Scholarship Donations From Pharmaceutical Companies to Japanese Healthcare Institutions in 2017: A Cross-sectional Analysis. International Journal of Health Policy and Management. 12. 7621–7621. 4 indexed citations

Ozierański, Piotr, et al.. (2023). Professional and governmental policy on community pharmacy: A 10-year policy review and comparative analysis (2008–2017). SHILAP Revista de lepidopterología. 11. 100298–100298. 2 indexed citations

Carmel, Emma, et al.. (2023). Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis. BMJ Open. 13(3). e061591–e061591. 3 indexed citations

Murayama, Anju, Sae Kamamoto, Yudai Kaneda, et al.. (2022). Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self‐Citation Rate in Japan and the United States. Arthritis Care & Research. 75(6). 1278–1286. 14 indexed citations

Ozierański, Piotr, et al.. (2021). A ‘patient–industry complex’? Investigating the financial dependency of UK patient organisations on drug company funding. Sociology of Health & Illness. 44(1). 188–210. 11 indexed citations

Ozierański, Piotr, et al.. (2021). Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review. BMJ Open. 11(12). e053138–e053138. 17 indexed citations

Ozierański, Piotr, et al.. (2020). Underreporting of drug industry payments to patient organisations in the UK (2012-2016). Pure (University of Bath). 1 indexed citations

10.

Ozierański, Piotr, et al.. (2020). Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016). BMJ Open. 10(9). e037351–e037351. 12 indexed citations

11.

Löblová, Olga, Marcell Csanádi, Piotr Ozierański, et al.. (2019). Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology. Health Policy. 123(7). 630–634. 12 indexed citations

12.

Csanádi, Marcell, Piotr Ozierański, Olga Löblová, et al.. (2019). Shedding light on the HTA consultancy market: Insights from Poland. Health Policy. 123(12). 1237–1243. 4 indexed citations

13.

Löblová, Olga, Marcell Csanádi, Piotr Ozierański, et al.. (2019). Patterns of alternative access: Unpacking the Slovak extraordinary drug reimbursement regime 2012-2016. Health Policy. 123(8). 713–720. 11 indexed citations

14.

Ozierański, Piotr, et al.. (2019). Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. Health Policy. 123(12). 1244–1250. 18 indexed citations

15.

Cohen, Deborah, Shai Mulinari, & Piotr Ozierański. (2019). The whistleblowing drama behind Astellas’s suspension from the ABPI. BMJ. 366. l4353–l4353. 5 indexed citations

16.

Mulinari, Shai & Piotr Ozierański. (2018). Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts. BMJ Open. 8(10). e023094–e023094. 39 indexed citations

17.

Csanádi, Marcell, Olga Löblová, Piotr Ozierański, et al.. (2018). When health technology assessment is confidential and experts have no power: the case of Hungary. Health Economics Policy and Law. 14(2). 162–181. 19 indexed citations

18.

Power, Maxine, Liz Brewster, Gareth Parry, et al.. (2016). Multimethod study of a large-scale programme to improve patient safety using a harm-free care approach. BMJ Open. 6(9). e011886–e011886. 8 indexed citations

19.

Gornall, Jonathan, et al.. (2016). A pill too hard to swallow: how the NHS is limiting access to high priced drugs. BMJ. 354. i4117–i4117. 18 indexed citations

20.

Ozierański, Piotr, Martin McKee, & Lawrence King. (2011). Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?. Health Economics Policy and Law. 7(2). 175–195. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact